Physiomics to attend BioForward 2024

Physiomics to attend BioForward 2024

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it is attending BioForward 2024, OBN’s  ‘Roadmap for Growth’ Life Sciences event, in Oxford on 24th of September 2024. The event attended by leaders of R&D companies across all therapeutic areas aims to create connections within industry that can catalyse growth of life science companies. 

 

Physiomics’ CEO, Dr Peter Sargent will be attending BioForward to meet with the leaders of drug development companies working across all indications and therapeutic modalities to identify opportunities where Physiomics’ expertise in Model-Informed Drug Development (MIDD) can inform or de-risk their development decisions.  

 

Dr Peter Sargent, CEO, commented: “I’m really excited to attend BioForward to meet with leaders of early-stage and emerging biotech’s that can reap the benefits of early integration of Model Informed Drug Development in their pipeline strategy. An area that is rightfully getting more and more attention in drug development.” 

 

If you are interested in meeting at BioForward, please contact us through the partnering system. 

 

We look forward to seeing you there! 

 

 

Enquiries: 

Physiomics plc 

Dr Peter Sargent, Chief Executive Officer

+44 (0)1865 784 980 

 

Hybridan LLP (Broker) 

Claire Louise Noyce 

+44 (0) 203 764 2341 

 

Strand Hanson Ltd (NOMAD) 

James Dance & James Bellman 

+44 (0)20 7409 3494 

 

 

 

Notes to Editor 

   

About Physiomics 

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies. 

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.